Table 1.

Baseline demographics and clinical characteristics of individuals with and without type 2 diabetes remission, from LABS and LookAHEAD cohorts combined.

	Non-Remitters	Remitters	p
n	86	87
Intervention (%)			0.03
AGB	17 (19.8)	5 (5.7)
RYGB	29 (33.7)	42 (48.3)
DSE	7 (8.1)	7 (8.0)
ILI	33 (38.4)	33 (37.9)
Age (years)	54.95 (8.75)	53.28 (9.25)	0.22
Female (%)	62 (72.1)	56 (64.4)	0.35
White (%)	62 (72.1)	73 (83.9)	0.09
Baseline HbA1c (%)	7.21 (1.27)	6.44 (0.79)	<0.001
HbA1c at yr 2 (%)	6.73 (1.02)	5.38 (0.40)	<0.001
HbA1c at yr 4/5 (%)	7.12 (1.27)	5.46 (0.43)	<0.001
Baseline BMI (kg/m2)	43.5 (6.6)	44.6 (7.6)	0.33
Weight change at yr 2 (%)	−14.5 (13.4)	−23.8 (13.1)	<0.001
Weight change at yr 4/5 (%)	−12.6 (14.5)	−20.8 (13.3)	<0.001
Waist circumference (cm)	128.4 (16.4)	130.9 (17.2)	0.32
Fasting glucose (mg/dl)	144.4 (51.0)	127.7 (31.5)	0.01
Fasting insulin (uU/ml)	25.1 (22.4)	24.4 (14.4)	0.80
HOMA-IR	7.54 (8.26)	7.68 (4.61)	0.9
HOMA-B	113.9 (75.0)	165.8 (138.1)	0.008
CHOL (mg/dl)	183.4 (36.9)	184.9 (38.1)	0.78
HDL (mg/dl)	42.9 (10.1)	41.4 (11.3)	0.35
LDL (mg/dl)	104.4 (34.4)	102.8 (31.8)	0.76
TRIG (mg/dl)	188.4 (103.4)	222.9 (173.0)	0.11
Serum creatinine (mg/L)	0.79 (0.25)	0.82 (0.27)	0.47
hs-CRP (mg/L)	0.75 (1.03)	0.74 (0.83)	0.92
Metformin use at baseline (%)	55 (64.7)	48 (55.2)
	0.26
# Non-insulin T2D meds at baseline (%)			0.03
0	13 (15.3)	24 (27.6)
1	40 (47.1)	42 (48.3)
2	22 (25.9)	19 (21.8)
3	10 (11.8)	2 (2.3)
Using insulin at baseline (%)	24 (27.9)	4 (4.6)	<0.001

Data presented as mean (SD) for continuous variables and n (%) for categorical variables. AGB adjustable gastric banding, RYGB Roux-en-Y gastric bypass, ILI intensive life style intervention, DSE diabetes education.